Wang G, Hansen H, Tatsis E, Csernok E, Lemke H, Gross W L
Department of Clinical Rheumatology, Bad Bramstedt GmbH, Medical University of Lübeck, Germany.
Am J Med. 1997 Jun;102(6):517-23. doi: 10.1016/s0002-9343(97)00049-1.
To determine the plasma levels of soluble CD30 (sCD30) in Wegener's granulomatosis (WG) patients, and to investigate the possible correlation of sCD30 with disease extent and activity.
sCD30 was determined by radioimmunoassay in 57 WG patients, 25 patients with rheumatoid arthritis (RA), 23 patients with bacterial infections and 21 healthy controls (HC). The extent and activity of WG disease were assayed according to disease extent index (DEI) and standard laboratory parameters.
Plasma sCD30 levels in generalized WG (22.5 +/- 1.5 U/mL), but not in initial phase WG (12.1 +/- 4.0 U/mL), were significantly increased compared with HC (8.8 +/- 0.9 U/mL, P < 0.0001). Furthermore, of 11 generalized WG patients who received long-term follow-up, sCD30 levels declined when the disease activity changed from active disease to remission (29.1 +/- 1.9 U/mL to 15.9 +/- 1.8 U/mL, P = 0.0001). Similar results were observed in the whole group of generalized WG, eg, sCD30 levels in active disease (29.4 +/- 1.4 U/mL) were significantly higher than in partial remission (17.9 +/- 1.9 U/mL, P < 0.001) and in complete remission (13.7 +/- 3.3 U/mL, P < 0.001). No significant difference was noted between complete remission and HC. In addition, sCD30 levels were correlated with other parameters of disease extent and activity such as DEI, plasma levels of sIL-2R, PR3-ANCA, ESR and CRP. The sCD30 levels were increased in RA patients compared with HC (15.2 +/- 2.1 U/mL, P < 0.05), but no correlation was found between disease activity parameters and sCD30 levels. In contrast, in patients with bacterial infections sCD30 levels (6.9 +/- 0.9 U/mL) were not significantly different compared with HC.
Plasma levels of sCD30 are not only significantly increased but also correlate with disease extent and activity in generalized WG. These findings suggest that sCD30 can act as a useful marker for evaluation of disease extent and activity, and that generalized WG may be associated with Th2-type immune response.
测定韦格纳肉芽肿(WG)患者血浆中可溶性CD30(sCD30)水平,并研究sCD30与疾病范围及活动度之间的可能相关性。
采用放射免疫分析法测定57例WG患者、25例类风湿关节炎(RA)患者、23例细菌感染患者及21名健康对照者(HC)的sCD30水平。根据疾病范围指数(DEI)和标准实验室参数评估WG疾病的范围及活动度。
与HC(8.8±0.9 U/mL,P<0.0001)相比,全身性WG患者的血浆sCD30水平(22.5±1.5 U/mL)显著升高,而疾病初期的WG患者(12.1±4.0 U/mL)则无明显升高。此外,在11例接受长期随访的全身性WG患者中,当疾病活动度从活动期转变为缓解期时,sCD30水平下降(从29.1±1.9 U/mL降至15.9±1.8 U/mL,P=0.0001)。在全身性WG患者的整个队列中也观察到了类似结果,例如活动期疾病患者的sCD30水平(29.4±1.4 U/mL)显著高于部分缓解期(17.9±1.9 U/mL,P<0.001)和完全缓解期(13.7±3.3 U/mL,P<0.001)。完全缓解期患者与HC之间未发现显著差异。此外,sCD